5 Key Takeaways
-
1
The OPTIC trial is a phase 1 multicenter trial focusing on gene therapy for wet age-related macular degeneration (AMD).
-
2
Ixo-vec demonstrated an 86% annualized reduction in anti-VEGF injections through years 2, 3, and 4 after a single injection.
-
3
The trial analyzed two doses, with the lower dose (2E11) showing no significant safety issues such as hypotony or vasculitis.
-
4
Mild cases of intraocular inflammation were treated with topical corticosteroids in the lower dose group.
-
5
The lower dose (2E11) had similar aqueous protein levels compared to the higher dose, leading to a phase 2 trial.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
